GSK has joined Chai Discovery’s growing roster of Big Pharma clients, signing up to access protein-folding and design models.

Becton, Dickinson and Company has named Ferass Abuzaina as its new Worldwide President of its Surgery business unit. | Becton ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

What does it mean to be a Fierce 15 biotech in 2026? With this year’s list unveiled, the Fierce Biotech team gets together to ...

Endeavor BioMedicines has solidified its potential threat to Big Pharma with a phase 2b readout suggesting its Hedgehog inhibitor could become the first drug to reduce lung fibrosis while increasing ...

Zealand Pharma has reported more phase 2 data on its Roche-partnered amylin analog, linking the drug candidate to competitive ...

Japan’s Ono Pharmaceutical is paying $80 million upfront for the regional rights to a trio of Biohaven’s IgG degraders led by ...

Caribou Biosciences, the off-the-shelf cell therapy outfit that spun out of Nobel Laureate Jennifer Doudna’s lab in 2011, is ...

To a passerby, the glass-fronted 10 Prospect building rising above the low-slung restaurant and retail space of Somerville's ...

Genentech is paying Alector $100 million upfront for exclusive rights to a preclinical drug candidate that targets a driver ...

TCGX is expanding its operations to Asia in connection with the fund, opening offices in Shanghai and Hong Kong. Dandan Dong, ...

Cadrenal Therapeutics, a heart-focused biotech that recently reached an agreement with the FDA on the design of a pivotal ...